IPM Take
Personalised prevention depends on identifying which children benefit from treatment, not assuming that a result applies equally across a trial population. The FDA’s review of SYD-101 raises questions about missing data, treatment durability and whether favourable subgroup findings can reliably guide prescribing. For IPM, the opportunity is to connect earlier risk assessment with stronger evidence standards: treatment selection should reflect demonstrated benefit, while promising subgroup signals should inform prospective research rather than become premature rules for care.
Executive Summary
An FDA briefing for its 30 October 2026 advisory committee meeting examined SYD-101, an investigational 0.01% atropine eye drop intended to slow childhood myopia. Its pivotal randomised trial enrolled 852 children aged 3–14 years. Confirmed progression beyond 0.75 dioptres occurred in 39.5% receiving 0.01% atropine versus 49.3% receiving vehicle control by month 36. Although the prespecified primary analysis met statistical significance, FDA reviewers questioned clinical meaningfulness, substantial missing data and declining benefit over time. They also reported no significant effect on axial length, the eye’s front-to-back dimension. More favourable findings in younger children and faster progressors remained exploratory. The briefing is a regulatory review document, not a final approval decision or a verdict on all atropine formulations.
Why it matters
- Clinicians: The review illustrates why statistical significance, structural outcomes and sustained benefit should be considered together. Exploratory subgroup findings do not establish a validated method for selecting children for this product.
- Public authorities: The case provides an opportunity to examine what constitutes meaningful evidence for preventive treatment in children. Commissioning and reimbursement discussions should distinguish a regulatory briefing from a final decision.
- Patients and advocates: Families need clear explanations of what slowing myopia means, how benefit is measured and what remains uncertain. The questions raised concern this application and its supporting evidence, rather than proving that every atropine concentration or formulation is ineffective.
A childhood myopia treatment can produce a statistically positive trial result and still leave a harder question unanswered: is the benefit large and reliable enough to matter?
That distinction sits at the centre of an FDA briefing prepared for the Dermatologic and Ophthalmic Drugs Advisory Committee meeting on 30 October 2026. Reviewers examined SYD-101, an investigational atropine sulfate eye drop at a concentration of 0.01%, and identified uncertainties about its effectiveness.
The document offers a useful lesson for preventive ophthalmology: an encouraging headline result is the beginning of evidence assessment, not its conclusion.
Why slowing myopia matters
Myopia, or short-sightedness, occurs when light focuses in front of the retina rather than directly on it, making distant objects appear blurred. Progressive myopia commonly involves elongation of the eye.
The concern extends beyond stronger spectacles. High myopia is associated with greater lifetime risks of retinal detachment, myopic maculopathy—damage affecting central retinal vision, glaucoma and cataracts. Earlier onset is also associated with faster progression and greater eventual severity.
This creates a preventive rationale for slowing progression during childhood. However, it does not establish that every treatment producing a small change in prescription will meaningfully reduce those later complications.
What the trial measured
The pivotal SYD-101-001 study enrolled 852 children aged 3–14 years with mild-to-moderate myopia across 47 clinical sites. Participants were randomly assigned to 0.01% atropine, 0.03% atropine or vehicle control: the comparison eye drop without the active drug. The principal treatment period lasted 36 months. The primary endpoint assessed confirmed myopic progression beyond 0.75 dioptres, a measure of optical power, at or before that time.
Progression occurred in 39.5% of participants receiving 0.01% atropine and 49.3% receiving vehicle. The FDA reported an adjusted treatment difference of −9.6 percentage points, with a 95% confidence interval from −17.9 to −1.3 percentage points. This adjusted estimate should not be confused with a simple subtraction of the displayed percentages.
The lower concentration met the prespecified statistical criterion; the 0.03% concentration did not. Reviewers considered the absence of a clear dose–response relationship another reason for caution.
Why reviewers remained concerned
Missing information was a major issue. Approximately 26% of participants in the 0.01% group lacked primary outcome data at month 36, compared with approximately 23% in the vehicle group.
The primary analysis used statistical methods to account for missing observations. However, a sensitivity analysis showed that a small change in assumptions about the missing values removed statistical significance. Reviewers therefore questioned how robust the positive result was.
They also questioned its clinical importance. The reported difference in mean annual progression was 0.079 dioptres per year over three years, while the between-group difference in progression at three years was 0.21 dioptres. FDA reviewers judged this magnitude unlikely to produce a meaningful improvement in how patients function or feel. That is the review team’s assessment, not a final regulatory determination.
The apparent benefit also diminished over time. Importantly, the trial did not demonstrate a significant effect on axial length, the eye’s front-to-back dimension. Because elongation is central to progressive myopia, reviewers considered this relevant to claims of disease modification and future risk reduction.
Personalised medicine opportunity
Some subgroup findings appeared more favourable in children aged 3–12 years and in children whose myopia had progressed faster before enrolment. These observations are relevant to a personalised approach, but they do not yet establish who should receive this product.
The FDA noted that the subgroup comparisons lacked the statistical safeguards needed to control the risk of chance-positive findings across multiple analyses. Although the subgroups had been prespecified, reviewers regarded their results as exploratory and hypothesis-generating.
For personalised medicine, the distinction is fundamental. Finding an apparently responsive group after examining trial results is different from prospectively demonstrating that a defined characteristic predicts treatment benefit.
An editorial implication is that future studies should test selection rules directly. Age and prior progression could inform research designs, but should not be presented as validated prescribing criteria on the strength of these analyses alone.
Looking ahead
The briefing explicitly states that its assessments do not necessarily represent the FDA’s final position. It cannot establish the advisory committee’s subsequent conclusions or the application’s eventual regulatory outcome.
Nor should its concerns be generalised to all myopia-control options. Separately, the FDA authorised Essilor Stellest spectacle lenses in September 2025 for a defined population of children aged 6–12 years at treatment initiation. That authorisation rests on a different device, evidence package and regulatory pathway.
The broader lesson is about matching preventive ambition to evidential strength. Children and families need explanations that distinguish slowing prescription change from reducing eye elongation, and both from demonstrating fewer serious complications decades later.
Personalised myopia care will advance when better identification of risk is matched by equally reliable evidence of benefit.

